Bridge Medicines announced today an agreement with Weill Cornell Medicine to develop a novel sphingosine 1-phosphate (S1P) receptor modulator. This small molecule program originated in the laboratory of Timothy Hla, Ph.D. formerly of Weill Cornell Medicine, now Boston Children's Hospital, and was successfully advanced by the Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI). The Tri-I TDI was formed in 2013 with support from Takeda Pharmaceutical Company Limited and enables early-stage drug discovery work in a collaborative academic setting. The recently completed S1P receptor modulator program from Hla's laboratory is one of approximately 50 programs within the Tri-I TDI pipeline.